To view this email as a web page, click here.
August 26, 2019
 
Anti-VEGFs pose no additional risk of SAEs over other therapies
image description here Here’s why it is increasingly evident that these medications are well tolerated systemically when delivered as intravitreal pharmacotherapy for sight-threatening retinal disease, including in the real-world treatment of DME.
Learn more
ADVERTISEMENT
 
Retina risk app tool empowers diabetic patients worldwide
image description here Find out how a novel app is helping diabetic patients assess their risk for the development of diabetic eye disease and set goals accordingly.

Read more
 
Migraines and retinal perfusion: A headache for physicians, patients
image description here Optical coherence tomography angiography can detect microcirculatory disturbances during acute attacks.

Read more
 
RELATED ARTICLES
 
US, international physicians mostly in agreement over treatment practices
Global trends show similar patterns worldwide
Obesity + diabetic retinopathy: Korean study explores inverse association
DNA analysis: Unraveling role of genetics in DR pathogenesis
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.